Full Press Release Details
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor.
IDYA
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
Key Takeaway: IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib a cMET Inhibitor
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma